century chemical evaluation. We suggest that one factor limiting greater model application is the need for increased awareness and agreement of what chemical exposure assessment encompasses within the risk assessment paradigm. This is of particular importance today because of the increased availability of computational and high-throughput data and methods for chemical assessment allowing evaluators to potentially examine exposure from site of release to site of toxic action, thus linking exposure with toxicology. We further suggest there is a need for discussion at a global level to promote the awareness of new tools and approaches available for fate and exposure modeling and suggest that this could be organized using the aggregate exposure pathways concept.
No takes yet. Share an insight, caveat, or question.
Bonnell et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: